POLYESTRADIOL PHOSPHATE (160 MG MONTH) OR LHRH ANALOG (BUSERELIN DEPOT) IN THE TREATMENT OF LOCALLY ADVANCED OR METASTASIZED PROSTATIC-CANCER/

The clinical efficacy, cardiovascular complications and mortality of p olyestradiol phosphate (PEP) 160 mg/month i.m. were compared with the luteinizing hormone releasing hormone (LHRH) analog, buserelin, in a p rospective, randomised multicentre study including 147 patients with p rostatic cancer. The cumulative non-progression rate at three years wa s 0.53 in the PEP group and 0.70 in the LHRH group. The mortality from cardiovascular diseases was the same in the two treatment groups. The parenterally given PEP was not associated with an increased risk of c ardiovascular complications. The dosage of PEP 160 mg monthly seems, h owever, to be insufficient in the treatment of prostatic cancer.